Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03808922 · ClinicalTrials.gov registry record · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
A Phase 3 study of COVID-19 and Lower Respiratory Tract Infection, sponsored by Ansun Biopharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 274
- Enrollment target
- 20
- Study locations
NCT03808922: Recruiting Phase 3 study of COVID-19 and Lower Respiratory Tract Infection, sponsored by Ansun Biopharma.
NCT03808922 is a Phase 3 study of COVID-19 and Lower Respiratory Tract Infection that is actively recruiting participants, run by Ansun Biopharma. The registered enrollment target is 274 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03808922, a Phase 3 study of COVID-19 and Lower Respiratory Tract Infection, is actively recruiting participants, sponsored by Ansun Biopharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 274 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Primary Outcome
Removal of all oxygen support (with stable SpO2)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DAS181
- DRUG DAS181 COVID-19
- DRUG DAS181 OL
Study Locations (20)
California
- City of Hope cancer Center - Duarte
- UCLA - Los Angeles
- University of California Davis Health System - Sacramento
- University of California San Diego Medical Center - San Diego
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
- University of Chicago - Chicago
- Loyola University Medical Center - Maywood
Florida
- Sylvester Comprehensive Cancer Center, University of Miami Health System - Miami
- Houston Methodist Hospital - Tampa
Maryland
- University of Maryland - Baltimore
- The Johns Hopkins Hospital - Baltimore
Massachusetts
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Colorado
- Children's Hospital Colorado - Aurora
Iowa
- University of Iowa Health Care - Iowa City
Kansas
- University of Kansas Medical Center - Fairway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2019-05-23 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 3 |
What NCT03808922 shows while recruiting
NCT03808922 is an interventional study that assigns participants to a tested intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03808922 names 20 study sites across 12 states, led by California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT03808922 about?
NCT03808922 is a clinical study titled "Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study". This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
What is the current status of trial NCT03808922?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2019-05-23. Estimated completion is 2025-08-31.
What conditions does trial NCT03808922 study?
This clinical trial studies the following conditions: COVID-19, Lower Respiratory Tract Infection, Immunocompromised, Parainfluenza.
What interventions are being tested in trial NCT03808922?
The interventions under investigation include: Placebo (DRUG), DAS181 (DRUG), DAS181 COVID-19 (DRUG), DAS181 OL (DRUG).
Who is sponsoring clinical trial NCT03808922?
This trial is sponsored by Ansun Biopharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03808922 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03808922's enrollment target sits among peer trials
274 147th of 298 higher than 151 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
- NCT05952583 · 274 participants
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
- NCT06173401 · 274 participants · Phase 3
Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI